Taipei, Taiwan

Chia-Ching Ting

This inventor holds 1 USPTO granted patent. Top assignee: Sunny Pharmtech Inc.. Active years: 2018.


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Chia-Ching Ting in Pharmaceutical Composition

Introduction

Chia-Ching Ting is an accomplished inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative work on compositions that enhance the efficacy of expectorant agents.

Latest Patents

Chia-Ching Ting holds 1 patent for a pharmaceutical composition containing guaifenesin. This invention provides a unique formulation that includes a core containing guaifenesin, which is encapsulated by a coating layer. The coating layer consists of a plasticizer and a polymer, with the polymer content ranging from approximately 5 wt. % to 35 wt. % based on the total weight of the pharmaceutical composition. Additionally, the invention outlines a method for the controlled release of the expectorant agent, enhancing its therapeutic effectiveness.

Career Highlights

Chia-Ching Ting has been instrumental in advancing pharmaceutical technologies through his innovative approaches. His work has not only contributed to the development of effective medications but has also positioned him as a key figure in the pharmaceutical industry.

Collaborations

Chia-Ching Ting collaborates with Hao-Hsiang Hung, who is a talented woman in the field. Their partnership exemplifies the importance of teamwork in driving innovation and achieving breakthroughs in pharmaceutical research.

Conclusion

Chia-Ching Ting's contributions to pharmaceutical compositions demonstrate his commitment to improving healthcare solutions. His innovative patent on guaifenesin showcases the potential for advancements in expectorant therapies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…